ORIGINAL RESEARCH article

Front. Oncol.

Sec. Neuro-Oncology and Neurosurgical Oncology

Volume 15 - 2025 | doi: 10.3389/fonc.2025.1548276

This article is part of the Research TopicInnovative Approaches in Glioma Therapy: Exploring New Therapeutic FrontiersView all 6 articles

Efficacy and Safety of Low-dose X-rays Based Intraoperative Radiotherapy for High-Grade Gliomas: A Single-Center Retrospective Study

Provisionally accepted
Zhongcheng  WenZhongcheng Wen1Jun  LiuJun Liu2Yang  BaiYang Bai2Minghao  ZhouMinghao Zhou3Jiajie  HeJiajie He4Ying  XuYing Xu5Ying  YanYing Yan5Shun  GongShun Gong3*Jia-Nan  LiJia-Nan Li3*Peng  CaoPeng Cao2*
  • 1Dalian Medical University, Dalian, China
  • 2Northern Theater Command General Hospital, Shenyang, Liaoning Province, China
  • 3Department of Neurosurgery, Northern Theater General Hospital, Shenyang, Liaoning Province, China
  • 4Jinzhou Medical University, Jinzhou, Liaoning Province, China
  • 5Department of Radiology, Northern Theater General Hospital, Shenyang, Liaoning Province, China

The final, formatted version of the article will be published soon.

ABSTRACTBackground Intraoperative radiotherapy (IORT) is an emerging local therapy in the surgery of intra-axial brain tumors to improve clinical outcomes and accelerate the adjuvant oncologic therapy. Despite its use in neuro-oncology, the data regarding the role of IORT in the treatment of high-grade gliomas (HGGs) is sparse. Here we reported our single-institutional evidence concerning the efficacy and safety of IORT in the management of HGGs.MethodsA total of thirty patients diagnosed with HGGs who underwent surgical treatment and IORT at our center between October 2021 and October 2023 were included. Clinical data were collected and analyzed, including surgical parameters such as the gross total resection (GTR) rate, follow-up assessments of treatment responses (Karnofsky Performance Status [KPS] scores), treatment-related complications, overall survival (OS), and subsequent therapeutic interventions. Multivariable Cox regression analyses were performed to identify independent risk factors for survival in patients with HGGs.ResultsThe median IORT dose was 12 Gy prescribed to the applicator surface using the INTRABEAM system. The median OS was 11.0 months (IQR: 7.8–14.3), with a 1-year survival rate of 46.7%. No severe radiation-related adverse events, such as cerebral radiation necrosis or wound-related complications, were recorded. Kaplan-Meier analyses showed that patients who received post-operative radiotherapy and chemotherapy after IORT had better clinical outcomes than those who did not. Multivariable regression analyses indicated post-operative radiotherapy was independently correlated with favorable clinical outcomes.Conclusion Low-dose X-rays based IORT at doses of 10-12 Gy is generally safe for HGGs. Future prospective large-scale studies are needed to further evaluate the efficacy and safety of IORT with escalating doses. Even with the use of IORT, post-operative radiotherapy is essential for improving clinical outcomes of HGGs. This study provides clinical data on IORT for HGGs, which may represent a promising therapeutic approach for managing this disease.Keywords: High-grade gliomas; intraoperative radiotherapy; surgery; survival; efficacy; safety.

Keywords: high-grade gliomas, intraoperative radiotherapy, Surgery, Survival, efficacy, Safety

Received: 19 Dec 2024; Accepted: 14 Apr 2025.

Copyright: © 2025 Wen, Liu, Bai, Zhou, He, Xu, Yan, Gong, Li and Cao. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence:
Shun Gong, Department of Neurosurgery, Northern Theater General Hospital, Shenyang, Liaoning Province, China
Jia-Nan Li, Department of Neurosurgery, Northern Theater General Hospital, Shenyang, Liaoning Province, China
Peng Cao, Northern Theater Command General Hospital, Shenyang, 110017, Liaoning Province, China

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Research integrity at Frontiers

94% of researchers rate our articles as excellent or good

Learn more about the work of our research integrity team to safeguard the quality of each article we publish.


Find out more